Drug Trial Radar · NCT07284901
Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,270
Actual
Start
Jan 12, 2026
Primary completion
Mar 27, 2028
Study completion Apr 24, 2028
Sponsor
- Lead sponsor
- KaileraIndustry
- Sponsor type
- Industry
- First posted
- Dec 16, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to demonstrate that ribupatide (KAI-9531) subcutaneous (SC) injection once weekly is superior to placebo on: * Percent change in body weight * Change in hemoglobin A1c (HbA1c)
Conditions
- Obesity With Diabetes
- Overweight With Diabetes
Interventions
RibupatideDrug
SC Injection
PlaceboDrug
SC Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Doses 3 and 4 of Ribupatide Versus Placebo: Percent Change From Baseline in Body Weight at Week 76Time frame: Baseline, Week 76
- Doses 3 and 4 of Ribupatide Versus Placebo: Change From Baseline in HbA1c at Week 76Time frame: Baseline, Week 76
Locations
174 sites in 11 countries. Site status is shown where the registry gives one.
Kailera Clinical Site
Cullman, Alabama
Kailera Clinical Site
Phoenix, Arizona
Kailera Clinical Site
Sun City, Arizona
Kailera Clinical Site
Little Rock, Arkansas
Kailera Clinical Site
Escondido, California
Kailera Clinical Site
La Mesa, California
Kailera Clinical Site
Montclair, California
Kailera Clinical Site
Northridge, California
Kailera Clinical Site
Oceanside, California
Kailera Clinical Site
Toluca Lake, California
Kailera Clinical Site
Stamford, Connecticut
Kailera Clinical Site
Bradenton, Florida
Kailera Clinical Site
Hollywood, Florida
Kailera Clinical Site
Jupiter, Florida
Kailera Clinical Site
Miami, Florida
Kailera Clinical Site
Miami Lakes, Florida
Kailera Clinical Site
Orange City, Florida
Kailera Clinical Site
Orlando, Florida
Kailera Clinical Site
Orlando, Florida
Kailera Clinical Site
The Villages, Florida
Kailera Clinical Site
Decatur, Georgia
Kailera Clinical Site
Lilburn, Georgia
Kailera Clinical Site
Marietta, Georgia
Kailera Clinical Site
Riverdale, Georgia
Kailera Clinical Site
Skokie, Illinois
Kailera Clinical Site
Springfield, Illinois
Kailera Clinical Site
Newton, Kansas
Kailera Clinical Site
Shreveport, Louisiana
Kailera Clinical Site
Annapolis, Maryland
Kailera Clinical Site
Columbia, Maryland
Kailera Clinical Site
Boston, Massachusetts
Kailera Clinical Site
Farmington Hills, Michigan
Kailera Clinical Site
Missoula, Montana
Kailera Clinical Site
Lincoln, Nebraska
Kailera Clinical Site
Las Vegas, Nevada
Kailera Clinical Site
Albany, New York
Kailera Clinical Site
Laurelton, New York
Kailera Clinical Site
New York, New York
Kailera Clinical Site
Greensboro, North Carolina
Kailera Clinical Site
Monroe, North Carolina
Showing 40 of 174 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.